Lysostaphin, in vitro studies I SCHAFFNER, MELLY, HASH, KOENIG lysostaphin activity,2 residual lysostaphin was inactivated by adding trypsin (0.1 to 0.5% final concentration) to the pour plates.
Human leukocytes were obtained by dextran sedimentation of whole blood as previously described.' Washed leukocytes were suspended in 10% human serum in Hank's solution. Staphylococci were added in a ratio of one microorganism to one polymorphonuclear leukocyte and these mixtures were rotated on a drum at 370C.
Control~~~~~~~~~~~~~~~~ ( 1 6 The incorporation of labeled glycine* by lysostaphin-resistant staphylococci and the subsequent fractionation of the microorganism were performed as previously described.'6 Washed cells (12.8 mg. dry wt.) from the log phase of growth were suspended in 20 ml. of synthetic media containing 2.0 uic of 14C-glycine. Samples were incubated with shaking at 370C. and 5 ml. aliquots were withdrawn and fractionated as described. '6 After solubilization of the cell wall with the Chalaropsis N-acetylmuramidase, aliquots corresponding to 0.8 mg. dry weight cells were placed on a Sephadex G-25 column (1 x 25 cm.) and eluted with water. Fractions (0.7 ml.) were collected and added to 10 ml. of scintillation fluid and counted.' * Purchased from New England Nuclear Corporation as 14C-glycine, specific activity 74 mc/mmole.
RESULTS

In vitro activity of lysostaphin
Lysostaphin rapidly kills Staphylococcus aureus in zitro. As is demonstrated in Figure 1 , increasing doses of lysostaphin killed increasing numbers of staphylococci. Using 70 ,ug/ml. of lysostaphin, the bacterial population fell approximately two log units in one hour. Ten times as much OXACILLIN: 7Opg/ML (2) 704000jg/ML (2) -'8- lysostaphin reduced the viable count by five log units. Oxacillin, even in amounts one thousand times as large (70,000 ,ug/ml.), did not alter the population of a resting oxacillin-sensitive staphylococcal strain during this time period (Fig. 2) .
Temperatures between 220C. and 560C. had relatively little influence on the speed of bacterial killing. At room temperature (220C.), initial killing rates were less than those observed at 370C., but at the end of an hour similar degrees of killing had occurred. At 560C. lysostaphin remained actively lytic, but such temperatures alone killed staphylococci.
A number of staphylococcal strains have been described which produce diffuse streaming colonies in serum or plasma soft agar, have increased virulence for mice, possess antiphagocytic surface antigens, and appear encapsulated.68 Although only a few of these strains have been isolated from patients with active staphylococcal infection,8 it has been proposed that such strains represent the biological form of the disease-producing staphylococcus in vivo and may actually be responsible for more disease than is currently suspected."7 Studies were thus performed to determine whether the surface structures of such encapsulated strains would impair the action of lysostaphin. As noted in Figure 3 , this was not the case. Small quantities of lysostaphin (35 jug/ml.) were more active against an encapsulated strain than against a usual wild-type strain, while larger amounts of lysostaphin lysed encapsulated and wild-type staphylococci at similar rates.
Studies performed both in experimental animals"8"9 and in vitro"' have clearly demonstrated that bacteria which have reached maximal titers in tissue or in the test tube are relatively insusceptible to penicillin despite rapid killing of smaller numbers of these same bacteria during a phase of active multiplication. As Figure 4 demonstrates, lysostaphin was active against very large populations of staphylococci that were penicillin insusceptible. In this instance lysostaphin produced over a hundredfold reduction in a large population of microorganisms when penicillin G showed no activity over the six-hour period of study even though over 4,000 times the standard minimum inhibitory concentration of the drug was employed. Lysostaphin was relatively stable at 370C. and maintained its activity in human serum. Over a 36-day period of incubation at 370C. lysostaphin was slowly inactivated (Fig. 5A ), but the enzyme was still able to kill more than 99% of the staphylococci in one hour. In a system containing 220 Volume 39, February, 1967 Lysostaphin, in vitro studies SCHAFFNER, MELLY, HASH, KOENIG 50%o serum no alteration of lysostaphin activity could be detected (Fig.  5B) .
Lysostaphin activity was only slowly reduced after repeated exposure to staphylococci. As shown in Figure 6 , the addition of fresh populations of staphylococci at hourly intervals to buffer containing lysostaphin produced some reduction in staphylococcal killing after each successive staphylococcal challenge. However, after three additions of fresh staphylococci, over 91%o of the microorganisms were still killed during the fourth hour. The accumulation of inhibitory and toxic end products consequent to bacterial lysis provides the most likely explanation for the observed progressive decrease in lysostaphin activity. Lysostaphin controls incubated alone maintained full activity for the duration of the experiment.
Effect of intracellular residence on lysostaphin activity
Coagulase-positive staphylococci are able to survive for a prolonged time within polymorphonuclear leukocytes.2' Studies were thus undertaken to determine whether lysostaphin was active against such phagocytized staphylococci. These studies are represented in Figure 7 . When human leukocytes were allowed to phagocytize the Giorgio staphylococcus (a non-encapsulated strain) the intracellular population of staphylococci re- mained constant over the one-hour period of study. Lysostaphin (30 ,ug/ml.) had no effect on such intracellular staphylococci, while staphylococci alone were rapidly killed on exposure to lysostaphin. The intracellular position had protected the bacteria from lysostaphin action. Furthermore, if fresh leukocytes, extracellular staphylococci, and lysostaphin were simultaneously mixed together, rapid staphylococcal killing was initially observed. As phagocytosis proceeded and more staphylococci were ingested, killing slowed and then stopped.
In order to demonstrate that leukocytes did not inactivate the lysostaphin and thus, account for the observed impairment in killing, leukocytes were suspended in lysostaphin (35 jug/ml.) at 370C. for one hour. The leukocytes were then removed by centrifugation, staphylococci were added to the lysostaphin-containing supernate, and no impairment of lysostaphin activity was observed.
Leukocytes that had been exposed to high concentrations of lysostaphin (1,400 Ag/ml.) for 30 minutes at 370C. were twice washed in buffer and homogenized in a teflon grinder. No evidence of lysostaphin activity was obtained in such leukocyte homogenates. This finding suggests that, in the system described, lysostaphin did not enter leukocytes in appreciable amounts or was promptly inactivated by intracellular residence.
In vitro resistance to lysostaphin Lysostaphin-resistant microorganisms were easily recovered in vitro. The Giorgio strain of Staphylococcus aureus was exposed to 3,500 jug/ml. of lysostaphin at 370C. Aliquots were taken at intervals, plated without trypsin, and the few surviving colonies were isolated. Two chosen at random were studied further, as indicated in Table 1 . The colonial morphology of both variants differed from the parent strain. They grew in pearly translucent colonies rather than in the yellowwhite opaque colony of the parent staphylococcus. The variants had a prolonged lag phase of growth as compared to the parent strain, although identical titers were reached by 18 hours. Both variants and the parent 224 Volume 39, February, 1967 Lysostaphin, in vitro studies SCHAFFNER, MELLY, HASH, KOENIG strain were lysed by Group III phages; however, the variants were lysed by fewer typing phages. Both variants produced tube coagulase. Variant no. 1 produced primarily diffuse streaming colonies in plasma soft agar. Variant no. 2 did not produce clumping factor ("bound coagulase"). Neither of the two variant strains were mouse virulent when injected intraperitoneally. However, when mice were infected intravenously, the parent strain and variant no. 2 produced equivalent mortality rates while variant no. 1 killed significantly fewer mice (0.05 > p > 0.01).
While both lysostaphin-resistant variants and the parent strain produced penicillinase, the varients were significantly more sensitive to peni- Studies on the basis of lysostaphin resistance in Staphylococcus aureus. The peptidase in lysostaphin releases N-terminal glycine and alanine, thus cleaving the cross-linking polyglycine bridges which are unique to the cell wall of Staphylococcus aureus.' Resistance to lysostaphin might result from the absence of polyglycine structures in resistant variants or might be due to the inaccessibility of susceptible bonds through an alteration in the chemical or physical structure of the cell wall. The first possibility was tested by determining whether 14C-glycine could be incorporated into the cell wall. As shown in Table 2 , both variant strains were able to incorprate 14C-glycine into both cell wall and protein. Variant no. 2 incor-YALE JOURNAL OF BIOLOGY AND MIDICINE porated glycine into both cell wall and protein at a rate similar to that of the parent, whereas variant no. 1 incorporated considerably less label into its cell wall than did the control. Nevertheless, both resistant variants incorporated glycine into their cell wall structures and their insensitivity to lysostaphin could not be ascribed to a lack of cell wall glycine. The cell wall fractions were further examined by subjecting them to gel filtration on Sephadex G-25 to determine if the cell wall polymer were cross-linked. The Chalaropsis B enzyme cleaves at every N-acetylmuramic acid and if polyglycine bridges were not cross-linked the resulting disaccharide-peptide product would be eluted with low molecular-weight materials. The results, shown in Figure 8 , indicated that the product solubilized by the Chalaropsis B enzyme was still high molecular-weight material. Though there were some products of low molecular weight in variant No. 1, the resistance of these lysostaphin-resistant variants could not be ascribed to a lack of cross-linking in the cell wall. The mechanism of resistance is, therefore, more complex and possibly involves surface alterations that protect susceptible bonds.
DISCUSSION
The present in z4tro studies confirm that lysostaphin is a potent bacteriocidal agent. It maintains its activity in human serum, is stable at body temperature for long periods of time, and is capable of lysing repeated challenge inocula of staphylococci. Unlike penicillin it is active against large populations of metabolically quiescent staphylococci analogous to those found within staphylococcal abscesses. Thus lysostaphin would appear to have potential therapeutic advantages in the management of staphylococcal disease.
The finding that staphylococci residing within polymorphonuclear leukocytes were protected from lysostaphin action resembled results of experiments reported with penicillin. Tompsett has demonstrated that the activity of penicillin is greatly diminshed against such intracellular staphylococci.' Lysostaphin-resistant staphylococci were readily selected in vitro. However, they differed from the parent strain in several significant characteristics. While the two variants did not change their phage type, ability to produce coagulase, or mouse virulence when administered intraperitoneally, their colonial morphology was markedly altered, their lag phase of growth was greatly prolonged, and the variant most resistant to lysostaphin was significantly less virulent for mice when given by the intravenous route.
The decreased mouse virulence resembles the situation reported with laboratory produced penicillin-resistant staphylococci. These also appear to have diminished disease-producing potential.' Furthermore, both lysostaphin-resistant variants, while retaining their ability to produce penicillinase, were found to be significantly more sensitive to penicillin in vitro than was the parent staphylococcus. This suggests that the varients either produced less penicillinase or that their cell wall structure was altered so that they had become more susceptible to penicillin. If the latter were correct these strains might have been killed before significant quantities of penicillinase were produced.
The present studies suggest that resistance to lysostaphin is not related to a basic change in the chemical composition of the staphylococcal cell wall. The observed resistance to lysostaphin could not be attributed to the lack of glycine substrate or the absence of appropriate glycine cross-links in the cell walls of the resistant variants. These findings suggest that lysostaphin resistance may possibly relate to alterations in steric configurations at the surface of the cell wall preventing the apposition of lysostaphin and the susceptible bonds in the wall.
Because of its potent activity in vitro, its selectivity, and its effect on large populations of metabolically inactive staphylococci, it would appear that lysostaphin deserves study as a therapeutic agent in experimental staphylococcal infections.
SUMMARY
The in zvtro characteristics of lysostaphin, an enzyme that lyses the cell walls of staphylococci, were studied. Unlike the penicillins, lysostaphin rapidly killed large inocula of resting microorganisms. It maintained its activity in serum and for prolonged periods at 370C. The enzyme was equally active against encapsulated and non-encapsulated staphylococcal strains. Like penicillin, lysostaphin was inactive against intracellular staphylococci.
Lysostaphin-resistant staphylococci could be readily isolated in vitro. These resistant variants differed from the parent strain in their colonial morphology, slower growth rates, increased penicillin sensitivity, and, in one instance, diminished virulence for mice.
Studies of lysostaphin-resistant staphylococci suggested that resistance might possibly relate to configurational alterations on the surface of the cell wall rather than to changes in its chemical composition.
The impressive in vitro activity of lysostaphin indicates that this enzyme deserves further study as a therapeutic agent in experimental staphylococcal infections.
